Could a simple blood test tell some breast cancer patients It's safe to stop treatment?
NCT ID NCT06663787
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with HER2-positive metastatic breast cancer who have had a lasting response (complete or partial remission for over 2 years) on anti-HER2 therapy. Researchers will use a personalized blood test called Signatera to look for tiny amounts of cancer DNA. The goal is to see if this test can help guide future decisions about continuing or stopping treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab (Herceptin) and other anti-HER2 drugs
What this could lead to
If successful, this could help doctors decide whether some patients can safely stop or reduce their anti-HER2 therapy, potentially reducing side effects and treatment burden.
What could go wrong
This is a small, observational study (50 people) that only measures DNA in the blood—it does not test whether changing treatment is safe. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, 4678601, Japan
-
Nagoya City University
Nagoya, Aichi-ken, 4678601, Japan
-
Natera
San Carlos, Texas, 94070, United States
-
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Tokyo, Tokyo, 135-8550, Japan